MAR 1 4 2006

MAR 1			U.S. Patent are required to respond to a collection Application Number	Ap and Trac	pproved fo	or use through	PTO/SB/21 (02-04) h 07/31/2006. OMB 0651-0031 EPARTMENT OF COMMERCE
TO TRAD	Derwork Restriction Act of 1995.	, no persons	Application Number	10/	561,6	354 /	s a valio OMB control number.
TI	RANSMITTAL		Filing Date			per 20, 2	2005
	FORM		First Named Inventor		rtel		
(to be used for	all correspondence after initial	filing)	Art Unit				
(10 00 0000 101	an dan depondence and much	·····9/	Examiner Name	<u> </u>			
Total Number of	Pages in This Submission		Attorney Docket Number	21	733		
		ENCL	OSURES (Check all that	apply)			
Amendmu Ai Ai Ai Extension Express Ai Information Certified Documen Response Incomple	fter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority		Drawing(s) icensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Ferminal Disclaimer Request for Refund ED, Number of CD(s) USPTO Form 14 References			to Group Appeal Com of Appeals a Appeal Com (Appeal Notic Proprietary I	r sure(s) (please
<u> </u>	SIGNA	TURE O	F APPLICANT, ATTORNE	Y, OR	RAGE	NT	
Firm or Individual name Signature	Dennis P. Tram	naloni	1				
Date	03/10/2006	7/					
	l <u></u>	EDTIFIC	ATE OF TRANSMISSION	/8.4.A.11. 1			
I hereby certify th sufficient postage the date shown b	at this correspondence is b as first class mail in an en	eing facsin	ATE OF TRANSMISSION nile transmitted to the USPTO or of the commissioner for Pate	deposite	ed with the	he United S 450, Alexar	tates Postal Service with dria, VA 22313-1450 on
Typed or printed	Dennis P.	Trama	loni				
Signature	Du (7	Tan			Date	03/10/2006
This collection of inf	ormation is required by 37 CFR	R 1.5. The in	formation is required to obtain or retain	n a benefi	it by the p	public which is	s to file (and by the USPTO to

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Cornelia Hertel, et. al.

Group:

Application No. 10/561,654, filed December 20, 2005

Examiner:

(Case Docket No. 21733)

For: TRITIATED GROWTH HORMONE SECRETAGOGUE MK-0677

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 March 10, 2006

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B2 and C1-C11 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Appl. No. 10/561,654

Filed: December 20, 2005

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Dennis P. Tramaloni (Reg. No. 28,542)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4475

Telefax: (973) 235-2363

227862

OFF	2
MAR 1 4 200	915 304

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

of 1

Compl	ete if Known	
Application Number	10/561,654	
Filing Date	December 20, 2005	
First Name Inventor	Hertel	
Group Art Unit		
Examiner Name		
Attorney Docket Number	21733	

<u> </u>					NT DOCUMENTS	733		
	Τ	US	Patent Docu		11 DOCUMENTS		<u> </u>	
Examiner Initials'	Cite No.1	U.S. Patent Document Kind Code² Number (if known)			Name of Patentee or Applican Cited Document	Date of Publication of Cited document MM-DD-YYYY		
			F0	DEIGN DAG	PENT DOCUMENTS			
	T	Foreign I	Patent Docum		TENT DOCUMENTS	Dat	e of Publication of	Т°
Examiner Initials'	Cite No.¹	Office ³	Number*	Kind Code ⁵	Name of Patentee or Applicant of Cited Document	(Cited Document MM-DD-YYYY	•
	B1	EP 061	5977		Merck & Co., Inc.	12-	08-1993	
	B2	WO 97	22367		Merck & Co., Inc.	06-	26-1997	
		,						
Examiner		Date Cor	reidered					
Signature	itial if refere			tion is in conformance	with MPEP 609. Draw line through citation if not	in confor	mance and not considered. Inc	hide con

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

			for form 1449A/PTO	Complete if Known		
I	NFORMA	TION	DISCLOSURE	Application Number	10/561,654	
			Y APPLICANT	Filing Date	December 20, 2005	
				First Name Inventor	Hertel	
	(Use seve	ral shee	ets if necessary)	Group Art Unit		
				Examiner Name		
Sheet	2	Of	2	Attorney Docket Number	21733	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Smith, et. al., Science, 260, 1640-1643	
	C2	R. F. Walker, et. al., Neuropharmacol. 989, 28, 1139	
	C3	C.Y. Bowers, et. al., Biochem. Biophys. Res. Comm. 1991, 178, 31.	
	C4	Proc. Natl. Acad. Sci. USA, 92, 7001-7005 (July 1995)	
	C5	Hansch, et. al., J. Med. Chem. 1973, 16, 1207	
	C6	Dean, et. al. J. Med. Chem. 39, n.9, 1996, 1767-1770	
	C7	Jones, et. al., J. of Labelled Compounds, V.38, n.6, 1996, 561-565	
	C8 .	Pomes, et. al., Biochemical & Biophysical Research, V.225, 1996, 939-945	
	C9	Pong, Molecular Endocrinology, V. 10, n.1, 1996, 57-61	
	C10	Nagamine, J., J. of Endocrinology, V.171, n.3, 2001, 481-489	
	C11	Matuszewski, et. al., Chromatographia 2000, v.52, n. Suppl. S39-S45	
Examiner Signature		DATE	
orginature		CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

226067